G. Manikhas

891 total citations
25 papers, 681 citations indexed

About

G. Manikhas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, G. Manikhas has authored 25 papers receiving a total of 681 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in G. Manikhas's work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (7 papers) and Gastric Cancer Management and Outcomes (6 papers). G. Manikhas is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (7 papers) and Gastric Cancer Management and Outcomes (6 papers). G. Manikhas collaborates with scholars based in Russia, United States and Germany. G. Manikhas's co-authors include Sergey Cheporov, Paul Bhar, А. Н. Махсон, Alicia Clawson, D. Krasnojon, William J. Gradishar, José Iglesias, John R. McGuire, Mark A. Socinski and С. В. Орлов and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and British Journal of Cancer.

In The Last Decade

G. Manikhas

24 papers receiving 662 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Manikhas Russia	10	536	229	197	122	45	25	681
Sergey Cheporov Russia	8	495 0.9×	158 0.7×	188 1.0×	64 0.5×	47 1.0×	28	588
V. Georgoulias Greece	16	843 1.6×	267 1.2×	375 1.9×	275 2.3×	33 0.7×	38	1.0k
D. Bafaloukos Greece	13	566 1.1×	185 0.8×	112 0.6×	191 1.6×	37 0.8×	37	777
A. Lambiase Italy	17	613 1.1×	181 0.8×	92 0.5×	297 2.4×	39 0.9×	55	899
Bonne J. Adams United States	11	469 0.9×	264 1.2×	273 1.4×	387 3.2×	22 0.5×	26	824
Shude Cui China	14	290 0.5×	139 0.6×	276 1.4×	233 1.9×	56 1.2×	42	610
Robert N. Raju United States	16	667 1.2×	241 1.1×	178 0.9×	284 2.3×	15 0.3×	30	985
Neel I. Nissen Denmark	11	280 0.5×	93 0.4×	132 0.7×	202 1.7×	47 1.0×	18	600
H. A. Burris United States	17	534 1.0×	218 1.0×	92 0.5×	271 2.2×	28 0.6×	57	770

Countries citing papers authored by G. Manikhas

Since Specialization

Citations

This map shows the geographic impact of G. Manikhas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Manikhas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Manikhas more than expected).

Fields of papers citing papers by G. Manikhas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Manikhas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Manikhas. The network helps show where G. Manikhas may publish in the future.

Co-authorship network of co-authors of G. Manikhas

This figure shows the co-authorship network connecting the top 25 collaborators of G. Manikhas. A scholar is included among the top collaborators of G. Manikhas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Manikhas. G. Manikhas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Manikhas, G., et al.. (2019). INFLUENCE OF THE AGE FACTOR AND TUMOR IMMUNOPHENOTYPE ON THE EFFECTIVENESS OF CYTOREDUCTIVE OPERATIONS IN METASTATIC COLORECTAL CANCER. Voprosy Onkologii. 65(6). 855–862. 2 indexed citations

Ivantsov, Alexandr O., Alla Lisyanskaya, Laslo Roman, et al.. (2018). Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer. International Journal of Gynecological Cancer. 28(8). 1498–1506. 16 indexed citations

Кутукова, С. И., et al.. (2017). THE PROGNOSTIC VALUE OF PD-L1 EXPRESSION IN TUMOR AND IMMUNE CELLS IN SQUAMOUS CELL CARCINOMA OF THE ORAL MUCOSA. Voprosy Onkologii. 63(5). 759–765. 1 indexed citations

Manikhas, G., et al.. (2017). PREDICTIVE FACTORS IN THE CHOICE OF SURGICAL TREATMENT FOR COLORECTAL CANCER WITH LAPAROSCOPIC OR "OPEN" ACCESS. Voprosy Onkologii. 63(3). 470–474. 1 indexed citations

Tjulandin, Sergei, Sergey Cheporov, Vladimir Vladimirov, et al.. (2016). Phase I dose of oral quisinostat, in combination with gemcitabine (G) and cisplatin (Cis) or paclitaxel (P) and carboplatin (Carbo) in patients (pts) with non-small cell lung cancer or ovarian cancer (OC). Annals of Oncology. 27. vi123–vi123. 3 indexed citations

Lordick, Florian, Martin Schüler, S-E. Al-Batran, et al.. (2016). 220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer. Annals of Oncology. 27. ix69–ix69. 2 indexed citations

Al‐Batran, Salah‐Eddin, Martin Schüler, Zanete Zvirbule, et al.. (2016). FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology. 34(18_suppl). 35 indexed citations

Lisyanskaya, Alla, et al.. (2016). Aromatase inhibitors of the third generation in endocrine therapy of breast cancer and endometrial cancer: the successes and failures of the combination therapy. Reviews on Clinical Pharmacology and Drug Therapy. 14(2). 47–57.

Al-Batran, Salah-Eddin, Martin Schüler, Zanete Zvirbule, et al.. (2016). FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology. 34(15_suppl). LBA4001–LBA4001. 9 indexed citations

10.

Peeters, Marc, A. H. Strickland, Mikhail Lichinitser, et al.. (2013). A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. British Journal of Cancer. 108(3). 503–511. 60 indexed citations

11.

Gradishar, William J., D. Krasnojon, Sergey Cheporov, et al.. (2012). Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival. Clinical Breast Cancer. 12(5). 313–321. 91 indexed citations

12.

Thertulien, Raymond, G. Manikhas, Luc Dirix, et al.. (2011). Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies. Cancer Chemotherapy and Pharmacology. 69(2). 341–350. 7 indexed citations

13.

Socinski, Mark A., G. Manikhas, А. Н. Махсон, et al.. (2010). A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(6). 852–861. 67 indexed citations

14.

Smith, David C., Richard Eisenberg, Robert Stagg, et al.. (2010). 222 A first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with advanced solid tumors. European Journal of Cancer Supplements. 8(7). 73–73. 6 indexed citations

15.

Brugger, W., Nadja Triller, Maria Błasińska-Morawiec, et al.. (2009). Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. Journal of Clinical Oncology. 27(15_suppl). 8020–8020. 49 indexed citations

16.

Gradishar, William J., D. Krasnojon, Sergey Cheporov, et al.. (2009). Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer. Journal of Clinical Oncology. 27(22). 3611–3619. 260 indexed citations

17.

Gradishar, WJ, D. Krasnojon, Sergey Cheporov, et al.. (2008). Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC). European Journal of Cancer Supplements. 6(7). 172–172. 6 indexed citations

18.

Vukelja, Svetislava J., Joyce O’Shaughnessy, D. Krasnojon, et al.. (2008). Efficacy of Nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC). Journal of Clinical Oncology. 26(15_suppl). 1082–1082. 1 indexed citations

19.

Hawkins, Michael, G. Manikhas, А. Н. Махсон, et al.. (2007). Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 7659–7659. 5 indexed citations

20.

Eckardt, John R., Joachim von Pawel, G. Manikhas, et al.. (2005). Comparable activity with oral topotecan/cisplatin (TC) and IV etoposide/cisplatin (PE) as treatment for chemotherapy-naïve patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Final results of a randomized phase III trial (389). Journal of Clinical Oncology. 23(16_suppl). 7003–7003. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact